Results of this retrospective study based on a single-center cohort of metastatic melanoma patients treated with either single or double immune checkpoint inhibition show that OS is not always associated with baseline TB nor with baseline blood levels of LDH, S-100B or CRP; potentially widening treatments accessibility to patients currently excluded based on those baseline markers levels. Here, S100B is linked to metastatic melanoma.